The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study

Ítems similars

• Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
  per: Diafa, K, et al.
  Publicat: (2011)
• PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
  per: Pratsidou-Gertsi, P, et al.
  Publicat: (2013)
• The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
  per: Tzimouli, V, et al.
  Publicat: (2008)
• The portrait of Familial Mediterranean Fever in N. Greek pediatric patients: a 30-year experience
  per: Pratsidou-Gertsi, P, et al.
  Publicat: (2015)
• The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
  per: Trachana, M, et al.
  Publicat: (2011)